Isomer-Free Prostaglandin Synthesis via Macrolactonization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing Prostaglandin ester analogues, such as Latanoprost, Travoprost, and Tafluprost, result in significant production of unwanted 5,6-trans isomers, making it difficult to obtain isomer-free forms, especially in oil form, due to the limitations of common purification technologies like HPLC, which are costly and not suitable for mass production.
Innovation Solution
A novel process involving macrolactonization reactions with specific reagents and conditions to achieve high cis-selectivity, allowing for the removal of 5,6-trans isomers and resulting in isomer-free Prostaglandin analogues with improved crystallizability and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional Wittig reaction or conjugate addition methods are used to synthesize Prostaglandin ester analogues, then the synthesis process is straightforward and well-established, but unwanted 5,6-trans isomers are inevitably produced (2-10% or more), making it difficult to obtain isomer-free products
Solution Approach 1:
The patent changes the reaction parameters by using a macrolactonization reaction instead of conventional Wittig reaction or conjugate addition. This parameter change in the reaction type fundamentally alters the stereochemical outcome, achieving high cis-selectivity (5,6-cis isomer purity >99.5%) while maintaining practical synthetic utility through a straightforward one-step transformation.
2Manufacturing precision
If HPLC purification is used to remove 5,6-trans isomers, then isomer-free Prostaglandin analogues can be obtained, but the process becomes costly and unsuitable for mass production
Solution Approach 1:
The patent applies preliminary action by designing a synthesis route that produces predominantly the desired cis-isomer from the start ( >99.5% purity). This prevents the formation of unwanted trans-isomers rather than requiring their subsequent removal, thereby eliminating the need for costly HPLC purification and enabling direct mass production of isomer-free Prostaglandin analogues.
3Ease of manufacture
If trace amounts of enantiomers or isomers are present in commercially available starting materials, then the synthesis process is simple using off-the-shelf reagents, but the final product contains corresponding unwanted isomers
Solution Approach 1:
The patent converts the potential harm of trace impurities in commercially available starting materials into a benefit by using a macrolactonization reaction that exhibits high stereoselectivity. This reaction type inherently suppresses the formation of unwanted isomers from impurity starting materials, transforming a quality control problem into an advantage where commercial-grade reagents yield high-purity products without requiring ultra-pure starting materials.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process effectively reduces 5,6-trans isomer content to less than 0.5%, enabling the production of high-purity, isomer-free Prostaglandin analogues, enhancing their crystallinity and facilitating cost-effective mass production.
Implementation Method 1
treating a compound of formula IV-1 with S-pyridin-2-yl chloromethanethioate and triphenylphosphine to macrolactonize the compound
Data Source
AI summary
Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer:whereinR2, R3 and R4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.